All Pathways
Family MedicineManagement

Chronic Insomnia Evaluation & Management (AASM 2021)

Chronic Insomnia Evaluation & Management (AASM 2021): Insomnia Complaint → Comprehensive Sleep History → Secondary Causes? → Consider Sleep Study → Chro...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Insomnia Complaint

    Difficulty falling/staying asleep, ≥3x/week for ≥3 months, with daytime impairment

    1. Action

      Comprehensive Sleep History

      Characterize the insomnia

      • Sleep diary (2 weeks): bed/wake times, time to fall asleep, awakenings
      • Daytime consequences: fatigue, mood, concentration
      • Sleep environment: noise, light, temperature
      • Caffeine, alcohol, screen time patterns
      • Bed partner report: snoring, movements, apneas
      1. Decision

        Secondary Causes?

        Rule out other sleep disorders and contributors

        • Sleep apnea (STOP-BANG screen)
        • Restless legs syndrome
        • Depression/anxiety
        • Substance use
        • Medications causing insomnia
        • Pain, nocturia, other medical
        1. Action

          Consider Sleep Study

          If sleep apnea suspected

          • Home sleep test or PSG if STOP-BANG ≥3
          • PSG if treatment-refractory insomnia
          • Rule out PLMD, REM behavior disorder
          1. Action

            Chronic Insomnia Disorder

            Primary insomnia or comorbid insomnia

            • ≥3 months duration
            • Adequate sleep opportunity but difficulty sleeping
            • Daytime impairment present
            • Often perpetuated by maladaptive behaviors
            1. Action

              CBT-I (First-Line)

              Cognitive Behavioral Therapy for Insomnia

              • AASM STRONGLY recommends as first-line
              • Components: sleep restriction, stimulus control, cognitive restructuring
              • Delivered in-person, group, or digital (e.g., Sleepio, Somryst)
              • 6-8 sessions typical
              • Durable benefits (unlike medications)
              1. Action

                Sleep Hygiene Education

                Supportive but not sufficient alone

                • Regular sleep-wake schedule
                • Avoid caffeine after noon
                • Limit alcohol (disrupts sleep architecture)
                • Cool, dark, quiet bedroom
                • No screens 1h before bed
                • Use bed only for sleep and intimacy
              2. Decision

                CBT-I Response?

                Assess after 4-8 sessions

                1. Outcome

                  CBT-I Success

                  Maintain gains, booster sessions if needed

                2. Action

                  Pharmacotherapy (Second-Line)

                  If CBT-I insufficient or unavailable

                  • Short-term use preferred (<4 weeks)
                  • Suvorexant (orexin antagonist) - AASM recommended
                  • Low-dose doxepin (3-6mg)
                  • Z-drugs (zolpidem) - higher risk, short-term only
                  • Avoid benzodiazepines (tolerance, dependence)
                  1. Action

                    Medication Selection

                    Based on insomnia phenotype

                    • Sleep-onset: suvorexant, zolpidem, ramelteon
                    • Sleep maintenance: suvorexant, doxepin, extended-release zolpidem
                    • Comorbid depression: trazodone, mirtazapine
                    • Avoid diphenhydramine (anticholinergic, tolerance)
                    1. Warning

                      Refractory Insomnia

                      Specialty referral

                      • Sleep medicine referral
                      • Consider undiagnosed comorbidities
                      • Intensive outpatient CBT-I
                      • Address perpetuating factors (anxiety about sleep)

Guideline Source

AASM Clinical Practice Guideline for Chronic Insomnia in Adults

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • CBT-I delivery methods vary in availability
  • Sleep study indications simplified
  • Pharmacotherapy duration recommendations simplified
  • Does not address shift-work sleep disorder
  • Comorbid sleep disorders require specialized evaluation

Applicable Regions

USAUUKEU

AU: RACGP recommends CBT-I first-line

UK: NICE insomnia pathway favors behavioral approaches

US: AASM guidelines - CBT-I first-line

Version 1Next review: 2028-01-01

Frequently Asked Questions

What is the Chronic Insomnia Evaluation & Management (AASM 2021)?

The Chronic Insomnia Evaluation & Management (AASM 2021) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on AASM Clinical Practice Guideline for Chronic Insomnia in Adults.

What guideline is the Chronic Insomnia Evaluation & Management (AASM 2021) based on?

This algorithm is based on AASM Clinical Practice Guideline for Chronic Insomnia in Adults (DOI: 10.5664/jcsm.8236).

What are the limitations of the Chronic Insomnia Evaluation & Management (AASM 2021)?

Known limitations include: CBT-I delivery methods vary in availability; Sleep study indications simplified; Pharmacotherapy duration recommendations simplified; Does not address shift-work sleep disorder; Comorbid sleep disorders require specialized evaluation. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Chronic Insomnia Evaluation & Management (AASM 2021) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free